Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung, Seock‐Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altıntaş, Jan‐Willem Henning, Giuseppe Curigliano, José Manuel Pérez-García, Sung‐Bae Kim, Vanessa Petry, Chiun‐Sheng Huang, Wěi Li, Jean‐Sébastien Frenel, Silvia Antolín, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés
Topics & Concepts
TrastuzumabTrastuzumab emtansineMedicineOncologyMetastatic breast cancerBreast cancerInternal medicineCancerHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyAdvanced Breast Cancer Therapies